Background: Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. New studies show the effects of EPO on immune system. Objective: In this study, the effects of pretreatment with recombinant human erythropoietin (rHuEPO) on the anti-human leukocyte antibody (anti-HLA) titer were determined. Methods: Three groups of rats were sensitized with human...

background: erythropoietin (epo) was first known as a factor for red blood cell proliferation and differentiation. new studies show the effects of epo on immune system. objective: in this study, the effects of pretreatment with recombinant human erythropoietin (rhuepo) on the anti-human leukocyte antibody (anti-hla) titer were determined. methods: three groups of rats were sensitized with human...

recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. in clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (epo) increase cfu-e and diminish the number of granulocytes formed per culture plate. fetal progenitors are more sensitive to these effects of epo than progenitors from adults. we administered doses 50, 100, 200 iu/...

Recombinant human erythropoietin is a glycoprotein hormone that stimulates erythropoiesis. In clonogenic assays of hematopoietic progenitors, high concen-trations of erythropoietin (Epo) increase CFU-E and diminish the number of granulocytes formed per culture plate. Fetal progenitors are more sensitive to these effects of Epo than progenitors from adults. We administered doses 50, 100, 200 IU/...

Erythropoietin (EPO) was first known as a factor for red blood cell proliferation and differentiation. Recent studies show the effects of EPO on immune system. In this study the antihuman leukocyte antibody (anti-HLA) titer were determined in five groups of rats, which had been sensitized with human lymphocyte. Also, the effects of stimulation's frequency and dose of recombinant human erythropo...

erythropoietin (epo) was first known as a factor for red blood cell proliferation and differentiation. recent studies show the effects of epo on immune system. in this study the antihuman leukocyte antibody (anti-hla) titer were determined in five groups of rats, which had been sensitized with human lymphocyte. also, the effects of stimulation's frequency and dose of recombinant human eryt...

Anaemia is a common problem in end stage kidney disease. Recombinant human erythropoietin (rHuEPO) is commonly used in management of such patients to maintain optimal hemoglobin levels and to minimise transfusion requirements. Acquired pure red cell aplasia (PRCA) is a rare complication of erythropoietin therapy due to development of anti-erythropoietin antibodies (anti-EPOabs). We report a pat...

Expression of recombinant proteins and drugs in Pichia pastoris has been in development since the late 1980s and the number of recombinant proteins produced in P. pastoris has increased significantly in the past several years. Unlike bacteria, this strain is capable of producing complex proteins with post translational modifications such as correct folding, glycosylation, proteolytic maturation...

The pharmacokinetics of recombinant human erythropoietin (rHuEpo) administered intravenously has been investigated in a group of five patients with chronic renal failure who were dialysis-dependent. The half-life of circulating erythropoietin decreased from 7.9±OA hr (mean ±SO) at the beginning of treatment to 6.2±O.6 hr after 6 weeks and 5A±O.9 hr after 4 months of treatment. In spite of t...

The introduction of recombinant human erythropoietin (RHuEPO) has revolutionised the treatment of patients with anaemia of chronic renal disease. Clinical studies have demonstrated that RHuEPO is also useful in various non-uraemic conditions including haematological and oncological disorders, prematurity, HIV infection, and perioperative therapies. Besides highlighting both the historical and f...